Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aquivia Health vs AVARA Rx

Aquivia Health
Graded #80

Higher grade

vs+9.400000000000006
AVARA Rx
Graded #266

Lower grade

The verdict

Aquivia Health takes it — 72.2/100 to 62.8/100.

Aquivia Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Aquivia Health is a clinician-led, self-pay telehealth platform offering compounded GLP-1 therapy with the option to step up to branded Ozempic or Zepbound — an unusual side-by-side most compounded…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAquivia Health +43
86
43
Dose & formulationAquivia Health +8
85
77
Clinical oversightAVARA Rx +12
64
76
Labs & monitoringAquivia Health +1
53
52
FulfillmentAVARA Rx +6
71
77
Contract termsEven
55
55
Aquivia Health · left barAVARA Rx · right bar

The numbers

MetricAquivia HealthAVARA Rx
WeighScore72.2/10062.8/100
GradeCC
Scorecard rank#80#266
Semaglutide$149/mo$229/mo (starting dose, compounded)
Tirzepatide$179/mo$279/mo (starting dose, compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Aquivia Health

Graded #80 · C

Strengths

  • Clinical care provided by Open Loop Healthcare Partners, PC — a reused, verified MSO network
  • Named leadership: Steven Bishop MD (CMO), Phillip Gray PharmD (Chief Pharmacist), Tom Foster (President)
  • Itemized public pricing: compounded semaglutide $149/mo, tirzepatide $179/mo, Ozempic $1,299, Zepbound $1,399
  • Both compounded and branded GLP-1s offered side by side — unusual for a compounded provider
  • Self-pay model with no insurance required and no separate consultation fee

Where it loses points

  • No public list of states served — you must complete intake to learn if your state qualifies
  • No named 503A compounding pharmacy partner, limiting licensure verification
  • No LegitScript, PCAB, or BBB trust badges visible
  • Brand confusion: site schema names 'CatalystMD' while the customer-facing brand is Aquivia Health
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
AVARA Rx

Graded #266 · C

Strengths

  • Names its pharmacy partner (DiRx Health, Ft Lauderdale FL) — buyers can independently verify its licensure
  • Names its clinical network (Beluga Health) — you can research the platform handling your prescriptions
  • All 50 states explicitly listed on the FAQ — uncommon vs peers that just say 'nationwide'
  • Patient-friendly refunds — full refund if a provider disqualifies you, partial if a weaker dose is prescribed
  • LegitScript verification badge displayed; pharmacy claims NABP-accredited facilities

Where it loses points

  • Operating legal entity not disclosed — only a Sheridan, WY registered-agent-style address surfaced
  • Dose pricing not itemized — only 'starting at $229' semaglutide and 'starting at $279' tirzepatide
  • LegitScript certification number not shown — badge only, so no direct lookup
  • No named medical director (Beluga Health is the network, not a named MD)
  • Lab work requirements not specified, and consultation fee not broken out from medication cost

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard